#ESMO26 Nearly 1 in 3 patients alive at 7 years with EV+pembrolizumab in cisplatin-ineligible la/mUC - Mature EV-103 data (N=121; median follow-up 64.2 months).
🔹 ORR 66.9%; median DOR 29.6 months
🔹 41% of responders maintained response at 4 years
🔹 Median OS 27.7 months; 7-year OS 28.2%
🔹 Grade ≥3 TRAEs 64.5%; discontinuation of either agent 50.4%
🔹 No new safety signals
A remarkable long-term survival tail in cisplatin-ineligible la/mUC, reinforcing EV+P as 1L SOC
@UroToday @myESMO
39 浏览 · 1 赞 · 1 转发 · 0 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com